Skip to main navigation
Skip to search
Skip to main content
HSC Home
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Search by expertise, name or affiliation
Empagliflozin in heart failure with a preserved ejection fraction
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Empagliflozin in heart failure with a preserved ejection fraction'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Empagliflozin
100%
Heart Failure Hospitalization
55%
Patients with Heart Failure
33%
Confidence Interval
22%
Hazard Ratio
22%
Cardiovascular Mortality
22%
Placebo Groups
22%
Placebo
22%
Cardiovascular Hospitalizations
22%
Hospitalization Risk
22%
Preserved Ejection Fraction
22%
Hypotension
11%
Diabetes
11%
Heart Failure
11%
Once-daily
11%
Low Risk
11%
Ejection Fraction
11%
Without Diabetes
11%
Patients with Diabetes
11%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
11%
Urinary Tract Infection
11%
Number of Hospitalization
11%
Reduced Ejection Fraction
11%
Combined Risk
11%
Double-blind Trial
11%
Reproductive Tract Infections
11%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Empagliflozin
100%
Placebo
40%
Hypotension
10%
Cotransporter
10%
Urinary Tract Infection
10%
Fenyramidol
10%
Genital Tract Infection
10%